How Much Does Solriamfetol Cost Without Insurance in the UK?
Solriamfetol (brand name Sunosi) is a wake-promoting agent prescribed for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnoea. Without NHS funding or insurance cover, the full private cost for a standard 28-tablet pack typically ranges from £170 to £260, depending on the strength (75 mg or 150 mg) and the pharmacy supplying it.
Prices are estimates based on publicly available pharmacy and BNF data and may vary. Most patients start on 75 mg once daily and may titrate to 150 mg, so the higher-strength pack sits at the upper end of that range. In specialist sleep clinics we often observe that once patients understand the monthly commitment, many explore NHS specialist referral pathways first, yet private access remains a practical option for those who need immediate or ongoing treatment outside standard commissioning routes.
Price Comparison by Pharmacy Type
High-street and hospital pharmacies in larger cities frequently quote at the higher end of private pricing due to overheads and lower volume for this specialist medicine. Online pharmacies and specialist dispensers that handle private prescriptions (often with next-day discreet delivery) tend to offer more competitive rates, sometimes £10-£20 lower per pack through efficient sourcing.
Rural or independent outlets may add a modest premium for stock-holding and delivery logistics. No widespread national discount schemes or loyalty cards apply specifically to private solriamfetol, but some online providers bundle with consultation services. The real differentiator remains whether your case qualifies for NHS specialist commissioning rather than pure private payment.
Price Breakdown Table
| Type | Price Range (28 tablets) | Notes |
|---|---|---|
| Brand Sunosi 75 mg (private) | £170-£185 | Lower-strength starting dose |
| Brand Sunosi 150 mg (private) | £240-£260 | Higher-strength maintenance dose |
| Online/specialist pharmacies | £170-£255 | Often competitive with delivery options |
Generic vs Brand Price Difference
At present solriamfetol remains available only as the brand-name Sunosi in the UK; no approved generic versions have entered the market. This absence of competition keeps private costs at the full list price with no percentage savings available.
The situation stems from ongoing patent protections and the relatively recent UK approval pathway. In clinical practice we regularly see patients asking about generics, only to learn that the branded product meets the same MHRA standards for quality and efficacy, so the lack of alternatives does not affect therapeutic outcomes-just the wallet.
Dosage-Based Cost Differences
Solriamfetol is supplied in two strengths: 75 mg and 150 mg film-coated tablets. The 75 mg pack is noticeably cheaper (around £170-£185), while stepping up to 150 mg increases the cost by roughly £70 per 28-day supply. Titration usually begins at 75 mg for the first few days before moving to the maintenance dose if needed.
Standard packs contain 28 tablets (a full month’s supply), and larger quantities are rarely dispensed privately because of the medicine’s specialist status and storage requirements. Stable patients on 150 mg therefore face the higher monthly outlay, though some prescribers review dose reduction once symptoms stabilise to help manage long-term private costs.
Why Is Solriamfetol Expensive in the UK?
Several UK-specific factors drive the private price of solriamfetol. As a relatively new dopamine and norepinephrine reuptake inhibitor, it underwent a full NICE technology appraisal (TA758) that recommended it only for narcolepsy-related excessive daytime sleepiness after other treatments have been tried. This specialist-only positioning, combined with central NHS England commissioning in many regions, limits routine availability and keeps wholesale costs elevated.
You can review the current indicative pricing and medicinal forms directly on the British National Formulary solriamfetol page. The absence of generic competition further sustains the list price, while the medicine’s controlled distribution through sleep specialists adds pharmacy handling and monitoring overheads. Compared with older, cheaper stimulants, solriamfetol’s targeted mechanism and favourable side-effect profile justify its cost for suitable patients, yet private payers bear the full impact until local formularies or individual funding requests open NHS access.
How to Reduce Solriamfetol cost in the uk
The most effective route is discussing NHS eligibility with a sleep specialist or neurologist-many patients with confirmed narcolepsy meet NICE TA758 criteria and move to the standard prescription charge (£9.90 in England, free in Scotland, Wales and Northern Ireland). For those remaining private, request quotes from multiple online pharmacies before committing.
Consider starting at the lower 75 mg strength where clinically appropriate to test response and minimise initial outlay. In our experience supporting patients across the UK, those who combine specialist review with proactive price comparison across accredited online providers often keep monthly private costs closer to the lower end of the range while maintaining consistent symptom control.
Price Comparison Across Countries
The UK’s regulated pricing and NICE oversight keep private solriamfetol costs substantially lower than in the United States, where a 30-day supply without insurance can exceed $10,000. In Australia, access is more limited and private pricing aligns closer to UK levels but without equivalent central appraisal guidance.
For a fuller picture of wake-promoting agents, see how solriamfetol pricing compares in the UK and Australia under their respective national schemes.
Leave a Reply